Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening.

Levy M, Bonnet D, Mauge L, Celermajer DS, Gaussem P, Smadja DM.

PLoS One. 2013 Jun 10;8(6):e65114. doi: 10.1371/journal.pone.0065114. Print 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/ad9cc7fc-af50-4658-bd90-e3aaf0def017.

2.

Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1.

Li X, Qiu J, Pan M, Zheng D, Su Y, Wei M, Kong X, Sun W, Zhu J.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):10743-51. eCollection 2015.

3.

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension.

Smadja DM, Mauge L, Gaussem P, d'Audigier C, Israel-Biet D, Celermajer DS, Bonnet D, Lévy M.

Angiogenesis. 2011 Mar;14(1):17-27. doi: 10.1007/s10456-010-9192-y. Epub 2010 Nov 4.

4.

Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease.

Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhé PR, Bonnet D, Lévy M.

Circulation. 2009 Jan 27;119(3):374-81. doi: 10.1161/CIRCULATIONAHA.108.808246. Epub 2009 Jan 12.

5.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071
6.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ; FREEDOM-C2 Study Team.

Chest. 2013 Sep;144(3):952-958. doi: 10.1378/chest.12-2875.

PMID:
23669822
7.

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ.

Circulation. 2013 Feb 5;127(5):624-33. doi: 10.1161/CIRCULATIONAHA.112.124388. Epub 2013 Jan 10.

8.
9.

Evidence-based pharmacologic management of pulmonary arterial hypertension.

Benedict N, Seybert A, Mathier MA.

Clin Ther. 2007 Oct;29(10):2134-53. Review.

PMID:
18042471
10.

Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.

Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, Feinstein JA.

J Heart Lung Transplant. 2013 May;32(5):546-52. doi: 10.1016/j.healun.2013.01.1055. Epub 2013 Feb 28.

11.

Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.

Small M, Piercy J, Pike J, Cerulli A.

Adv Ther. 2014 Feb;31(2):168-79. doi: 10.1007/s12325-014-0094-z. Epub 2014 Jan 22.

PMID:
24449285
12.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

13.

[Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].

Kaemmerer H, Gorenflo M, Hoeper M, Huscher D, Ewert P, Pittrow D.

Dtsch Med Wochenschr. 2013 Jun;138(23):1247-52. doi: 10.1055/s-0033-1343189. Epub 2013 May 29. Review. German.

PMID:
23720182
14.

Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition.

Duffels M, van Loon L, Berger R, Boonstra A, Vonk-Noordegraaf A, Mulder B.

Congenit Heart Dis. 2007 Jul-Aug;2(4):242-9. doi: 10.1111/j.1747-0803.2007.00104.x. Erratum in: Congenit Heart Dis. 2009 Jan;4(1):74. Vonk-Noordergraaf, Anton [corrected to Vonk-Noordegraaf, Anton].

PMID:
18377475
16.

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

Farber HW, Miller DP, Meltzer LA, McGoon MD.

J Heart Lung Transplant. 2013 Nov;32(11):1114-22. doi: 10.1016/j.healun.2013.08.010. Epub 2013 Sep 10.

PMID:
24035189
17.

Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.

Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W, Kneussl MP, Lang IM.

J Thromb Haemost. 2007 Mar;5(3):483-9.

18.

Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease.

Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, Peyrard S, Sabatier F, Bonnet D, Lévy M.

Pediatr Cardiol. 2010 Jul;31(5):657-62. doi: 10.1007/s00246-010-9674-0. Epub 2010 Feb 27.

PMID:
20195855
19.

Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.

Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.

J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011. Epub 2011 May 4.

PMID:
21531577
20.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.

Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.

Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.

PMID:
20451700

Supplemental Content

Support Center